Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Stanford, California 94305


To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis.

Study summary:

To learn about the use of high dose chemotherapy followed by transplantation using peripheral blood stem cells.


Inclusion Criteria:1. Primary amyloidosis 2. Age < 75 years. 3. Patients must have their pathology reviewed and the diagnosis confirmed at Stanford University Medical Center. 4. Patients who have undergone bone marrow transplantation previously will not be eligible. 5. Patients must have a Karnofsky performance status greater than 70%. 6. Patients must have a serum creatinine less than 2 mg/dl or creatinine clearance greater than 30 ml/min, bilirubin less than 2 mg/dl, transaminases less than two times normal, left ventricular ejection fraction >45% on echocardiography, cardiac index > 1.8 liters/min/m^2 and pulmonary function tests demonstrating FEV1 and DLCO > 60%. 7. Patients must be HIV negative. 8. Pregnant or lactating women will not be eligible to participate. 9. Patients must provide signed informed consent. 10. Patients with multiple myeloma and amyloid are eligible. Exclusion Criteria:1. prior blood or marrow transplant



Primary Contact:

Principal Investigator
Sally Arai
Stanford University

Backup Contact:


Location Contact:

Stanford, California 94305
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.